CompletedPhase 3NCT04173494
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sierra Oncology LLC - a GSK company
- Principal Investigator
- Srdan Verstovsek, M.D., Ph.D., M.D., PhDDepartment of Leukemia, The University of Texas MD Anderson Cancer Center
- Intervention
- Momelotinib(drug)
- Enrollment
- 195 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2022
Study locations (30)
- Mayo Clinic Hospital - Phoenix, Phoenix, Arizona, United States
- Irvine Center for Clinical Research, Irvine, California, United States
- Norris Comprehensive Cancer Center, Los Angeles, California, United States
- American Institute of Research - Whittier, Whittier, California, United States
- University of Colorado Hospital Anschutz Cancer Pavilion, Aurora, Colorado, United States
- Georgetown University Medical Center, Washington D.C., District of Columbia, United States
- Moffitt Cancer Center, Tampa, Florida, United States
- Northwest Oncology & Hematology - Rolling Meadows, Rolling Meadows, Illinois, United States
- Washington University School of Medicine in Saint Louis, St Louis, Missouri, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- Columbia University Irving Medical Center - Presbyterian Hospital, New York, New York, United States
- Cleveland Clinic - Richard E. Jacobs Health Center, Avon, Ohio, United States
- Gabrail Cancer Center, Canton, Ohio, United States
- University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
- Allegheny Health Network, Pittsburgh, Pennsylvania, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04173494 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.
- RECRUITINGPHASE2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd.